Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $20.83 Average Target Price from Brokerages

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $23.3333.

ADPT has been the topic of a number of recent research reports. TD Cowen upped their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday. BTIG Research boosted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday. Guggenheim upped their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th.

Insider Activity

In other news, insider Francis Lo sold 51,004 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the sale, the insider directly owned 237,688 shares of the company’s stock, valued at $5,336,095.60. This represents a 17.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the sale, the insider owned 812,058 shares in the company, valued at $17,775,949.62. This trade represents a 37.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 1,305,787 shares of company stock worth $27,828,563. 5.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ADPT. Caitong International Asset Management Co. Ltd purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth $28,000. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. lifted its holdings in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $51,000. Finally, Strive Financial Group LLC acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $52,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

Adaptive Biotechnologies Trading Down 6.7%

Shares of Adaptive Biotechnologies stock opened at $22.57 on Wednesday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 3.22. The firm has a fifty day moving average price of $19.43 and a 200 day moving average price of $16.66. Adaptive Biotechnologies has a 1 year low of $9.96 and a 1 year high of $24.57. The stock has a market cap of $3.61 billion, a PE ratio of -55.05 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) earnings per share. Equities research analysts predict that Adaptive Biotechnologies will post -0.46 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.